BRCA2 and cancer: Most recently, based on cancer-specific mortality/morbidity benefit, the ESMO Precision Oncology Working Group recommended that the clinical testing panel should include eight genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1, and TP53 [14].